Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate.

Stevenson MD, Wailoo AJ, Tosh JC, Hernandez-Alava M, Gibson LA, Stevens JW, Archer RJ, Simpson EL, Hock ES, Young A, Scott DL.

J Rheumatol. 2017 Jul;44(7):973-980. doi: 10.3899/jrheum.160941. Epub 2017 Feb 15.

PMID:
28202743
2.

Health state utility values for diabetic retinopathy: protocol for a systematic review and meta-analysis.

Sampson CJ, Tosh JC, Cheyne CP, Broadbent D, James M.

Syst Rev. 2015 Feb 21;4:15. doi: 10.1186/s13643-015-0006-6. Review.

3.

Cost-effectiveness of combination nonbiologic disease-modifying antirheumatic drug strategies in patients with early rheumatoid arthritis.

Tosh JC, Wailoo AJ, Scott DL, Deighton CM.

J Rheumatol. 2011 Aug;38(8):1593-600. doi: 10.3899/jrheum.101327. Epub 2011 May 15.

PMID:
21572149
4.

Bridging the gap between methods research and the needs of policy makers: a review of the research priorities of the National Institute for Health and Clinical Excellence.

Longworth L, Sculpher MJ, Bojke L, Tosh JC.

Int J Technol Assess Health Care. 2011 Apr;27(2):180-7. doi: 10.1017/S0266462311000043. Epub 2011 Mar 29. Review.

PMID:
21447260
5.

Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals.

Tosh JC, Longworth LJ, George E.

Value Health. 2011 Jan;14(1):102-9. doi: 10.1016/j.jval.2010.10.015.

Supplemental Content

Support Center